Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (DE:0K4)
FRANKFURT:0K4
RESEARCH TOOLSreports
Holding DE:0K4?
Track your performance easily
0K4 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€16.50 - €32.78
Previous Close€27.1
Volume0.00
Average Volume (3M)N/A
Market Cap
€1.96B
Enterprise Value€1.31B
Total Cash (Recent Filing)$717.25M
Total Debt (Recent Filing)$35.73M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Mar 13, 2025EPS Estimate
-€1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding69,799,148
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.72
Forecast
1Y Price Target
€52.38Price Target Upside93.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Akero Therapeutics News
PremiumCompany Announcements
Akero Therapeutics Advances in MASH Treatment Trials
PremiumPre-Earnings
Is AKRO a Buy, Before Earnings?
Options Prices
Currently, No data available
---
Ownership Overview
3.53% Insiders
24.21% Mutual Funds
44.09% Other Institutional Investors
14.88% Public Companies and
Individual Investors
0K4 FAQ
What was Akero Therapeutics Inc’s price range in the past 12 months?
Akero Therapeutics Inc lowest stock price was €16.50 and its highest was €32.78 in the past 12 months.
What is Akero Therapeutics Inc’s market cap?
Currently, no data Available
When is Akero Therapeutics Inc’s upcoming earnings report date?
Akero Therapeutics Inc’s upcoming earnings report date is Mar 13, 2025 which is in 81 days.
How were Akero Therapeutics Inc’s earnings last quarter?
Akero Therapeutics Inc released its earnings results on Nov 08, 2024. The company reported -€1.013 earnings per share for the quarter, missing the consensus estimate of -€0.848 by -€0.165.
Is Akero Therapeutics Inc overvalued?
According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued.
Does Akero Therapeutics Inc pay dividends?
Akero Therapeutics Inc does not currently pay dividends.
What is Akero Therapeutics Inc’s EPS estimate?
Akero Therapeutics Inc’s EPS estimate is -€1.12.
How many shares outstanding does Akero Therapeutics Inc have?
Akero Therapeutics Inc has 69,799,150 shares outstanding.
What happened to Akero Therapeutics Inc’s price movement after its last earnings report?
Akero Therapeutics Inc reported an EPS of -€1.013 in its last earnings report, missing expectations of -€0.848. Following the earnings report the stock price went down -1.83%.
Which hedge fund is a major shareholder of Akero Therapeutics Inc?
Among the largest hedge funds holding Akero Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Akero Therapeutics Inc’s shares valued at 49M.
---
Akero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€52.38 (93.29% Upside)
€52.38 (93.29% Upside)
Insider Transactions
Sold Shares
Worth $520.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.08%
12-Months-Change
Fundamentals
Return on Equity
-35.90%
Trailing 12-Months
Asset Growth
28.68%
Trailing 12-Months
Company Description
Akero Therapeutics Inc
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
---
0K4 Stock 12 Month Forecast
Average Price Target
€52.38
▲(93.29% Upside)
Technical Analysis
Akero Therapeutics
―
89bio
―
Prime Medicine, Inc.
―
Terns Pharmaceuticals
―
Viking Therapeutics
―
Best Analysts Covering 0K4
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+21.75%
assigned a buy rating 7 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +21.75% per trade.
---